Market Research Logo

Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

The global prostate cancer diagnostics market size is expected to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 12.3% during the forecast years. Demand for prostate cancer diagnostics is increasing owing to rising prevalence of the disease along with constant technological advancements and awareness regarding the same.

Every year, more than 2,30,000 men are diagnosed with prostate cancer. In addition, as per a study conducted by the American Cancer Society, prostate cancer is the third leading cause of cancer-related deaths in U .S. Constant development of new technologies for the disease diagnosis and treatment would drive the market over the coming years.

Magnetic Resonance Imaging (MRI) technology and Fusion biopsy are the new technologies used for the disease diagnosis. Fusion biopsy is a technique, which uses the combination of MRI and ultrasound. Some of the leading companies in the prostate cancer diagnostics market are MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.

Further key findings from the study suggest:

  • Increasing prevalence of prostate cancer is primarily boosting the market growth across the globe
  • Growing awareness regarding the disease and available treatments along with supportive government initiatives would also drive the market
  • The preliminary tests segment captured the largest market share of prostate cancer diagnostics in 2016
  • Confirmatory tests segment is said to expand at the fastest CAGR due to low risk of infection, convenience, and non-invasive nature of these tests
  • North America is dominant regional market followed by Europe due to sophisticated healthcare infrastructure and availability of technologically advanced products
  • Key companies in the market include MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.


Chapter 1 Research Methodology
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
1.3 Region Wise Market Calculation
1.3.1 Region Wise Market: Base Estimates
1.3.2 Global Market: CAGR Calculation
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of prostate cancer
3.1.1.2 Increasing government initiatives
3.1.1.3 Technological advancements
3.1.2 Market Restraint Analysis
3.1.2.1 High cost of diagnosis
3.2 Penetration & growth prospect mapping
3.3 Prostate Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis
4.1 Prostate cancer diagnostics market: Type movement analysis
4.2 Preliminary Tests
4.3 Confirmatory Tests
4.3.1. Confirmatory Tests Market Estimates & Segment Forecast, 2014 - 2025 (USD Million)
4.3.2 PCA3Test
4.3.2.1 PCA3Test Market, 2014 - 2025 (USD Million)
4.3.3 Trans-rectal ultrasound
4.3.3.1 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
4.3.4 Biopsy
4.3.4.1 Biopsy Market, 2014 - 2025 (USD Million)
Chapter 5 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Type
5.1 Prostate Cancer Diagnostics Market: Regional Movement Analysis
5.2 Prostate cancer diagnostics market share by region, 2015 & 2025
5.3 North America
5.3.1 North America market, 2014 - 2025 (USD Million)
5.3.2 U.S.
5.3.2.1 U.S. market, 2014 - 2025 (USD Million)
5.3.3 Canada
5.3.3.1 Canada market, 2014 - 2025 (USD Million)
5.4 Europe
5.4.1 Europe market, 2014 - 2025 (USD Million)
5.4.2 U.K.
5.4.2.1 U.K. market, 2014 - 2025 (USD Million)
5.4.3 Germany
5.4.3.1 Germany market, 2014-2025 (USD Million)
5.5 Asia Pacific
5.5.1 Asia Pacific market, 2014 - 2025 (USD Million)
5.5.2 Japan
5.5.2.1 Japan market, 2014 - 2025 (USD Million)
5.5.3 China
5.5.3.1 China market, 2014 - 2025 (USD Million)
5.6 Latin America
5.6.1 Latin America market, 2014 - 2025 (USD Million)
5.6.2 Brazil
5.6.2.1 Brazil market, 2014 - 2025 (USD Million)
5.6.3 Mexico
5.6.3.1 Mexico market, 2014 - 2025 (USD Million)
5.7 MEA
5.7.1 MEA market, 2014 - 2025 (USD Million)
5.7.2 South Africa
5.7.2.1 South Africa market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Company Profiles
6.2.1 MDxHealth
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 3D Signatures
6.2.2.1 Company overview
6.2.2.2 Product benchmarking
6.2.2.3 Strategic initiatives
6.2.3 Genomic Health
6.2.3.1 Company overview
6.2.3.2 Financial Performance
6.2.3.3 Product Benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Abbott
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.5 OPKO Health, Inc.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.6 Siemens Healthcare GmbH
6.2.6.1 Company overview
6.2.6.2 Financial Performance
6.2.6.3 Product benchmarking
6.2.7 DiaSorin S.p.A.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 bioMérieux SA
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.9 F. Hoffman La Roche Ltd.
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 Beckman Coulter, Inc.
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.11 Myriad Genetic, Inc.
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Product benchmarking
6.2.11.4 Strategic Initiatives
List of Tables
TABLE 1 North America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 2 U.S. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 3 Canada Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 4 Europe Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 5 Germany Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 6 U.K. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 7 Asia-Pacific Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 8 Japan Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 9 China Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 10 Latin America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 11 Brazil Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 12 Mexico Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 13 Middle East & Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
TABLE 14 South Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary (USD Million), 2015
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Prostate Cancer Diagnostics market: Type outlook key takeaways
FIG. 16 Prostate Cancer Diagnostics: Type Movement Analysis, USD Million
FIG. 17 Preliminary Tests Market, 2014 - 2025 (USD Million)
FIG. 18 Confirmatory Tests Market, 2014 - 2025 (USD Million)
FIG. 19 PCA3Test Market, 2014 - 2025 (USD Million)
FIG. 20 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
FIG. 21 Biopsy Market, 2014 - 2025 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Prostate Cancer Diagnostics Market: Regional Movement Analysis, USD Million
FIG. 24 North America market, 2014 - 2025 (USD Million)
FIG. 25 U.S. market, 2014 - 2025 (USD Million)
FIG. 26 Canada market, 2014 - 2025 (USD Million)
FIG. 27 Europe market, 2014 - 2025 (USD Million)
FIG. 28 U.K. market, 2014 - 2025 (USD Million)
FIG. 29 Germany market, 2014 - 2025 (USD Million)
FIG. 30 Asia Pacific market, 2014 - 2025 (USD Million)
FIG. 31 Japan market, 2014 - 2025 (USD Million)
FIG. 32 China market, 2014 - 2025 (USD Million)
FIG. 33 Latin America market, 2014 - 2025 (USD Million)
FIG. 34 Brazil market, 2014 - 2025 (USD Million)
FIG. 35 Mexico market, 2014 - 2025 (USD Million)
FIG. 36 MEA market, 2014 - 2025 (USD Million)
FIG. 37 South Africa market, 2014 - 2025 (USD Million)
FIG. 38 Strategy framework

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report